RxDoctor Payments Data

Venkateswarlu Thota, MD

Cardiovascular Disease · Wichita Falls, TXNPI 1437111697

Payments from drug & device makers

$23,313in general payments, 2019–2025

Across 529 payments — averaging $44.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Penumbra, Inc.$4K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Pfizer$3K
  • Abiomed$2K
  • Novartis$779
  • plus $7K from 37 others

What the payments were for

  • Consulting fees$2501%
  • Speaking & faculty fees$3,85017%
  • Travel & lodging$4,37019%
  • Food & beverage$14,73063%
  • Education$1130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,313 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$702,672
Medicare patients
2,163
Services billed
8,485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban993$906,863
XareltoRivaroxaban84$78,690
EntrestoSacubitril/Valsartan76$69,341
Repatha SureclickEvolocumab31$17,398
JardianceEmpagliflozin15$16,333
BrilintaTicagrelor14$14,554
FarxigaDapagliflozin Propanediol22$13,743
Metoprolol Succinate594$7,384
Ranolazine ErRanolazine62$7,153
Valsartan264$6,271
Atorvastatin Calcium814$5,461
Nitroglycerin PatchNitroglycerin126$4,051
ClopidogrelClopidogrel Bisulfate421$3,849
Carvedilol424$3,605
Chlorthalidone220$3,433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$2,852$906,863993 claims
Johnson & JohnsonXarelto$152$78,69084 claims
NovartisEntresto$779$69,34176 claims
AstraZenecaBrilinta, Farxiga$617$28,29736 claims
Boehringer IngelheimJardiance$445$16,33315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Wichita Falls

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →